Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Onco-Innovations Ltd. ( (TSE:ONCO) ) has shared an announcement.
Onco-Innovations Limited has announced the commencement of manufacturing preclinical testing material for its PNKP inhibitor technology by Dalton Pharma Services. This marks a significant step from early-stage research to production, supporting preclinical studies and regulatory preparations for an IND submission in the U.S. The company’s PNKP inhibitor, A83B4C63, has shown promising results in preclinical studies, extending survival in colorectal cancer models and enhancing tumor growth delay when combined with radiation therapy.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company focused on cancer research and treatment, specializing in oncology. The company is dedicated to the prevention and treatment of cancer through pioneering research and innovative solutions, with an exclusive worldwide license to patented technology targeting solid tumors.
Average Trading Volume: 127,266
For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.